Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Other Non-Current Assets (2019 - 2025)

Vivos Therapeutics has reported Other Non-Current Assets over the past 7 years, most recently at $228000.0 for Q4 2025.

  • Quarterly Other Non-Current Assets rose 5.56% to $228000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $228000.0 through Dec 2025, up 5.56% year-over-year, with the annual reading at $228000.0 for FY2025, 5.56% up from the prior year.
  • Other Non-Current Assets was $228000.0 for Q4 2025 at Vivos Therapeutics, up from $211000.0 in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $374648.0 in Q2 2021 and troughed at $211000.0 in Q3 2025.
  • The 5-year median for Other Non-Current Assets is $308000.0 (2023), against an average of $307259.8.
  • Year-over-year, Other Non-Current Assets grew 15.21% in 2021 and then tumbled 30.19% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $356000.0 in 2021, then rose by 5.06% to $374000.0 in 2022, then decreased by 17.91% to $307000.0 in 2023, then fell by 29.64% to $216000.0 in 2024, then increased by 5.56% to $228000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Other Non-Current Assets are $228000.0 (Q4 2025), $211000.0 (Q3 2025), and $255000.0 (Q2 2025).